Issue 3, 2021

Chemogenomics for drug discovery: clinical molecules from open access chemical probes

Abstract

In recent years chemical probes have proved valuable tools for the validation of disease-modifying targets, facilitating investigation of target function, safety, and translation. Whilst probes and drugs often differ in their properties, there is a belief that chemical probes are useful for translational studies and can accelerate the drug discovery process by providing a starting point for small molecule drugs. This review seeks to describe clinical candidates that have been inspired by, or derived from, chemical probes, and the process behind their development. By focusing primarily on examples of probes developed by the Structural Genomics Consortium, we examine a variety of epigenetic modulators along with other classes of probe.

Graphical abstract: Chemogenomics for drug discovery: clinical molecules from open access chemical probes

Article information

Article type
Review Article
Submitted
27 Jan 2021
Accepted
25 Mar 2021
First published
26 Mar 2021
This article is Open Access
Creative Commons BY license

RSC Chem. Biol., 2021,2, 759-795

Chemogenomics for drug discovery: clinical molecules from open access chemical probes

R. B. A. Quinlan and P. E. Brennan, RSC Chem. Biol., 2021, 2, 759 DOI: 10.1039/D1CB00016K

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements